|
||||
 |
||||
Dockets
Management
|
||||
|
Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee
Briefing Information Food and Drug Administration Briefing Document The
committee will discuss the agency’s draft recommendations
for relabeling of antihypertensive drugs for outcome claims,
as a follow-up to the committee’s meeting on Questions to the Committee –
Draft Guidance for Industry Session Draft Guidance for Industry: Labeling for outcome claims
for drugs to treat hypertension Food and Drug Administration Briefing Document The
committee will discuss the “Placebo in Hypertension Adverse
Reaction Meta-Analysis” (PHARM) Study, a meta-analysis of
more than 80,000 patients in placebo-controlled trials of
antihypertensive medications, which evaluated the risk of
irreversible harm in conducting placebo-controlled trials
in patients with hypertension Page last updated
April 25, 2006
kk |
